华润医药(03320.HK)治疗角结膜上皮损伤药物通过国家药监局一致性评价

阿斯达克财经11-19

华润医药(03320.HK) 公布，旗下华润紫竹药业收到国家药监局颁发的地夸磷索钠滴眼液《药品补充申请批准通知书》，并视同通过一致性评价，相关药物适用于经诊断为伴随泪液异常的角结膜上皮损伤的干眼患者。
据国家药监局信息显示，中国内地境内已批准上市的地夸磷索钠滴眼液生产企业共有29间，均视同通过一致性评价。

华润医药表示，上述药物获得《药品补充申请批准通知书》并视同通过一致性评价，将进一步丰富华润医药产品线，有助于提升公司产品的市场竞争力，对集团整体经营产生积极影响。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2024-11-18 16:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484596865?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240827115743024_s.jpg","is_english":false,"pubTime":"2024-11-19 12:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484596865","market":"hk","top_or_hot":-1,"title":"华润医药(03320.HK)治疗角结膜上皮损伤药物通过国家药监局一致性评价","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/03320\">华润医药</a>(03320.HK)<span> </span>公布，旗下华润紫竹药业收到国家药监局颁发的地夸磷索钠滴眼液《药品补充申请批准通知书》，并视同通过一致性评价，相关药物适用于经诊断为伴随泪液异常的角结膜上皮损伤的干眼患者。<br/>据国家药监局信息显示，中国内地境内已批准上市的地夸磷索钠滴眼液生产企业共有29间，均视同通过一致性评价。<br/><span></span><br/>华润医药表示，上述药物获得《药品补充申请批准通知书》并视同通过一致性评价，将进一步丰富华润医药产品线，有助于提升公司产品的市场竞争力，对集团整体经营产生积极影响。(js/w)<br/>(港股报价延迟最少十五分钟。沽空资料截至 2024-11-18 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华润医药(03320.HK)治疗角结膜上皮损伤药物通过国家药监局一致性评价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华润医药(03320.HK)治疗角结膜上皮损伤药物通过国家药监局一致性评价\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-11-19 12:28</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/03320\">华润医药</a>(03320.HK)<span> </span>公布，旗下华润紫竹药业收到国家药监局颁发的地夸磷索钠滴眼液《药品补充申请批准通知书》，并视同通过一致性评价，相关药物适用于经诊断为伴随泪液异常的角结膜上皮损伤的干眼患者。<br/>据国家药监局信息显示，中国内地境内已批准上市的地夸磷索钠滴眼液生产企业共有29间，均视同通过一致性评价。<br/><span></span><br/>华润医药表示，上述药物获得《药品补充申请批准通知书》并视同通过一致性评价，将进一步丰富华润医药产品线，有助于提升公司产品的市场竞争力，对集团整体经营产生积极影响。(js/w)<br/>(港股报价延迟最少十五分钟。沽空资料截至 2024-11-18 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397802/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1570","symbol_name":"华润系","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397802/latest-news/AAFN","article_id":"2484596865","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240827115743024_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484596865","pubTimestamp":1731990480,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"华润医药(03320.HK) 公布，旗下华润紫竹药业收到国家药监局颁发的地夸磷索钠滴眼液《药品补充申请批准通知书》，并视同通过一致性评价，相关药物适用于经诊断为伴随泪液异常的角结膜上皮损伤的干眼患者。据国家药监局信息显示，中国内地境内已批准上市的地夸磷索钠滴眼液生产企业共有29间，均视同通过一致性评价。华润医药表示，上述药物获得《药品补充申请批准通知书》并视同通过一致性评价，将进一步丰富华润医药产品线，有助于提升公司产品的市场竞争力，对集团整体经营产生积极影响。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-18 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1570":"华润系","BK1191":"制药","03320":"华润医药"},"translate_title":"China Resources Pharmaceutical (03320. HK) drug for treating keratoconjunctival epithelial injury passed the consistency evaluation of the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"华润医药(03320.HK) 公布，旗下华润紫竹药业收到国家药监局颁发的地夸磷索钠滴眼液《药品补充申请批准通知书》，并视同通过一致性评价，相关药物适用于经诊断为伴随泪液异常的角结膜上皮损伤的干眼患者。据国家药监局信息显示，中国内地境内已批准上市的地夸磷索钠滴眼液生产企业共有29间，均视同通过一致性评价。华润医药表示，上述药物获得《药品补充申请批准通知书》并视同通过一致性评价，将进一步丰富华润医药产品线，有助于提升公司产品的市场竞争力，对集团整体经营产生积极影响。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-18 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484596865"}